Diagnostic value and prognostic significance of CTRP9 combined with pentraxin‑3 in acute coronary syndrome

Abstract

The present study aimed to explore the diagnostic value and prognostic significance of C1q/tumor necrosis factor-related protein 9 (CTRP9) combined with pentraxin-3 (PTX-3) in acute coronary syndrome (ACS). A total of 137 patients with coronary heart disease and chest pain were included. Among them, seventy-nine patients with ACS were allocated into a study group and fifty-eight patients with non-cardiac chest pain (NCCP) were allocated into a control group. The serum CTRP9, PTX-3 levels were quantified by ELISA, and their correlation with other ACS-related indexes, diagnostic value for ACS and predictive significance for poor prognosis were analyzed. In addition, the risk factors of the poor prognosis of ACS patients were studied. CTRP9 was lowly expressed and PTX-3 was highly expressed in the serum of ACS patients. CTRP9 was negatively correlated with cardiac troponin I (cTnI), creatine kinase-MB (CK-MB) and high-sensitivity C-reactive protein (hs-CRP) (P<0.05), while PTX-3 was positively correlated with them (P<0.05). Combined detection of CTRP9 and PTX-3 was of high value in the diagnosis and prognosis of ACS patients. In addition, CTRP9 and PTX-3 were independent risk factors for the poor prognosis of ACS. Patients with ACS had lower CTRP9 expression and higher PTX-3 expression than those without ACS. Moreover, the combined detection of CTRP9 and PTX-3 can better evaluate the diagnosis and prognosis of ACS patients.

Higher Plasma Pentraxin-3 Level Predicts Adverse Clinical Outcomes in Patients With Coronary Artery Disease: A Meta-Analysis of Cohort Studies

“…Of these, 19 relevant records were further excluded for the reasons given in Figure 1. Finally, 16 cohort studies were obtained for the meta-analysis (13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28).…”

“…Overall, 16 cohort studies including 11,007 adults with CAD were included in the meta-analysis (13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28). These studies were published between 2004 and 2021 and most of the studies were prospective (13)(14)(15)(16)(17)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28), except one study, which was retrospective (18).…”

“…Overall, 16 cohort studies including 11,007 adults with CAD were included in the meta-analysis (13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28). These studies were published between 2004 and 2021 and most of the studies were prospective (13)(14)(15)(16)(17)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28), except one study, which was retrospective (18). For the subtype of CAD, four studies included patients with stable CAD (13,17,19,20), while the other studies included patients with ACS [7 patients with STEMI (14, 21-25, 27), two patients with NSTE-ACS (16,18), and three patients with both STEMI and NSTE-ACS (15,26,28)].…”

“…These studies were published between 2004 and 2021 and most of the studies were prospective (13)(14)(15)(16)(17)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28), except one study, which was retrospective (18). For the subtype of CAD, four studies included patients with stable CAD (13,17,19,20), while the other studies included patients with ACS [7 patients with STEMI (14, 21-25, 27), two patients with NSTE-ACS (16,18), and three patients with both STEMI and NSTE-ACS (15,26,28)]. One study reported outcome data in patients with STEMI and NSTE-ACS separately ( 15) and these datasets were independently included in the meta-analysis.…”

“…Moreover, in patients with stable CAD, peak PTX-3 values were also found to be correlated with plaque characteristics of the coronary arteries ( 13 ). However, studies evaluating the association between PTX-3 and prognosis in patients with CAD showed inconsistent results ( 13 – 28 ). An early meta-analysis including cohort studies before 2018 showed that elevated circulating PTX-3 may be associated with poor prognosis in patients with ACS, but not in patients with stable CAD ( 29 ).…”